Dr. P. Hoskins presented a Phase II trial of sequential couplets of cisplatin (DDP) and topotecan (TOP) and cisplatin and paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer on behalf of the National Cancer Institute of Canada. The dosage used were as follows:
DDP/TOP cycles: DDP 50 mg/m2 and TOP 0.75 mg/m2
DDP/T cycles: DDP 75 mg/m2 and T 135 mg/m2 IV infusion over 24 hours
Interval debulking was allowed.
Dr. Hoskins reported that:
Dose reduction was needed in 13% of DDP/TOP cycles
Dose delays were incurred in 9% of DDP/TOP cycles
A response rate of 85%
Dr. Hoskins concluded that:
Myelotoxcity of this couplet regimen is high but does not prevent delivery.
The response rate is encouraging being that these were predominately suboptimal patients.
This presentation was discussed by David Spriggs, M.D. from Memorial Sloan-Kettering Cancer Center. Dr. Spriggs had reservations:
Jun 4, 2013 - For women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone surgery and first-line chemotherapy, maintenance therapy with pazopanib is associated with significant longer median progression-free survival versus placebo, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.